Literature DB >> 31403859

Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer.

Charlie Gourley1, Michael A Bookman2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31403859     DOI: 10.1200/JCO.19.00337

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments.

Authors:  Xiaoying Chang; Dan Li; Chang Liu; Zhe Zhang; Tao Wang
Journal:  Cancer Cell Int       Date:  2021-04-06       Impact factor: 5.722

2.  An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear.

Authors:  Vincenzo Dario Mandato; Federica Torricelli; Stefano Uccella; Debora Pirillo; Gino Ciarlini; Gabriele Ruffo; Gianluca Annunziata; Gloria Manzotti; Sandro Pignata; Lorenzo Aguzzoli
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

3.  Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer.

Authors:  Jiashan Ding; Qiaoling Zhang; Shichao Chen; Huikai Huang; Linsheng He
Journal:  Aging (Albany NY)       Date:  2020-11-08       Impact factor: 5.682

4.  Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.

Authors:  Hao Lin; Wen-Hsin Chen; Chen-Hsuan Wu; Yu-Che Ou; Yu-Jen Chen; Ying-Yi Chen; Yu-Han Lin; Hung-Chun Fu
Journal:  Cancer Manag Res       Date:  2021-07-06       Impact factor: 3.989

5.  Silencing of the long noncoding RNA LINC01132 alleviates the oncogenicity of epithelial ovarian cancer by regulating the microRNA‑431‑5p/SOX9 axis.

Authors:  Wei Zhu; Xiangming Xiao; Jinqin Chen
Journal:  Int J Mol Med       Date:  2021-06-16       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.